Latest Innovation News

Activeport Group Ltd has successfully raised $6.68 million through a two-tranche placement, positioning the company to accelerate its software development and target cash flow positivity in FY26.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

JAYRIDE Group Limited has confirmed Randy Prado as CEO and Ram Navaratnam as Finance Director, cementing leadership as it advances its SaaS mobility platform with pilots in Southeast Asia.

Following its recent sale transaction, MPR Australia Limited announces significant board resignations alongside continued leadership under CEO Nathan Wise, signaling a strategic transition phase.

Bass Oil Limited reported a 20% increase in August sales revenue alongside a 3.5% rise in daily production, while progressing regulatory approval for its strategic Vanessa gas field acquisition.

Swift Networks secures a landmark Master Services Agreement with Opal HealthCare to deploy its innovative Swift TV platform across multiple aged care communities, marking a significant step in aged care technology integration.

NoviqTech has launched beta versions of its pioneering quantum AI products, QI Provenance and QI AI, marking a significant step toward commercialising hybrid quantum-classical computing solutions. The company also announced plans for a powerful CUDA-Q enhanced platform promising up to tenfold acceleration in complex computing tasks.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Andromeda Metals' latest Scoping Study reveals a compelling economic case for its innovative High Purity Alumina (HPA) production technology, highlighting strong returns and a significant carbon emissions advantage. The project aims to meet soaring global demand with a 10,000 tonne per annum facility in South Australia.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.